- Home
- SPFI vs TRVI Comparison
SPFI vs TRVI Comparison
Compare SPFI & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- TRVI
- Stock Information
- Founded
- SPFI 1941
- TRVI 2011
- Country
- SPFI United States
- TRVI United States
- Employees
- SPFI N/A
- TRVI N/A
- Industry
- SPFI Major Banks
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SPFI Finance
- TRVI Health Care
- Exchange
- SPFI Nasdaq
- TRVI Nasdaq
- Market Cap
- SPFI 662.8M
- TRVI 725.7M
- IPO Year
- SPFI 2019
- TRVI 2019
- Fundamental
- Price
- SPFI $39.29
- TRVI $7.96
- Analyst Decision
- SPFI Buy
- TRVI Strong Buy
- Analyst Count
- SPFI 3
- TRVI 9
- Target Price
- SPFI $41.67
- TRVI $20.72
- AVG Volume (30 Days)
- SPFI 43.0K
- TRVI 3.1M
- Earning Date
- SPFI 10-22-2025
- TRVI 11-05-2025
- Dividend Yield
- SPFI 1.49%
- TRVI N/A
- EPS Growth
- SPFI 19.09
- TRVI N/A
- EPS
- SPFI 3.20
- TRVI N/A
- Revenue
- SPFI $199,001,000.00
- TRVI N/A
- Revenue This Year
- SPFI $13.41
- TRVI N/A
- Revenue Next Year
- SPFI $6.10
- TRVI N/A
- P/E Ratio
- SPFI $12.61
- TRVI N/A
- Revenue Growth
- SPFI 7.49
- TRVI N/A
- 52 Week Low
- SPFI $30.01
- TRVI $2.36
- 52 Week High
- SPFI $42.38
- TRVI $9.92
- Technical
- Relative Strength Index (RSI)
- SPFI 45.89
- TRVI 51.91
- Support Level
- SPFI $39.40
- TRVI N/A
- Resistance Level
- SPFI $40.93
- TRVI $9.92
- Average True Range (ATR)
- SPFI 1.02
- TRVI 0.73
- MACD
- SPFI -0.21
- TRVI -0.24
- Stochastic Oscillator
- SPFI 5.76
- TRVI 80.24
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.